Holen Sie sich die Stockscreener-App
22.08
0.85%
-0.19
Vorhandelsmarkt:
22.39
0.31
+1.40%
Schlusskurs vom Vortag:
$22.27
Offen:
$22.3
24-Stunden-Volumen:
5.25M
Relative Volume:
1.79
Marktkapitalisierung:
$17.14B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.08B
KGV:
-15.28
EPS:
-1.4448
Netto-Cashflow:
$-326.53M
1W Leistung:
-12.21%
1M Leistung:
+42.08%
6M Leistung:
+14.52%
1J Leistung:
-39.84%
1-Tages-Spanne:
$21.45
$22.36
1-Wochen-Bereich:
$21.45
$29.23
52-Wochen-Spanne:
$13.83
$35.92
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.08 | 17.14B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
SMMT stock up 24% in three months: Here's what you need to know - MSN
Trading Systems Reacting to (SMMT) Volatility - Stock Traders Daily
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Summit Therapeutics shows rising price performance with jump to 82 RS rating - MSN
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.2%Time to Sell? - MarketBeat
Investors Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics (SMMT) jumps as investors refocus on upcoming ivonescimab data and bullish recent coverage - Quiver Quantitative
Positive Outlook for Summit Therapeutics (SMMT) Following ASCO P - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Sees Strong Trading VolumeHere's Why - MarketBeat
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim - TipRanks
Guggenheim Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Summit Therapeutics Inc. (SMMT): Investor Outlook on This Biotech Stock with 23.70% Potential Upside - DirectorsTalk Interviews
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio? - Benzinga
Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan
UBS reiterates Buy on Summit Therapeutics stock ahead of trial data - Investing.com Canada
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Summit Therapeutics has scarcity value in a crowded drug race: Analyst - MSN
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement - TradingKey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.2%Still a Buy? - MarketBeat
SMMT Stock Up 24% in Three Months: Here's What You Need to Know - Yahoo Finance
Been holding for so long - Moomoo
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - MSN
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - Stock Traders Daily
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - ADVFN
Aug PostEarnings: Can Summit Therapeutics Inc be the next market leader2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Inflation Data: Can Summit Therapeutics Inc stock outperform in a bear marketBreakout Watch & Stock Portfolio Risk Control - baoquankhu1.vn
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026 - Meyka
Stifel initiates coverage of Summit Therapeutics (SMMT) with buy recommendation - MSN
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Sahm
SMMT Upgraded to Buy by Citigroup on April 08, 2026 - Meyka
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
SMMT : POTENTIAL BOUNCEBACK Click Through The Up Coming Page (2dUA4zfHbg) - Mshale
SUMMIT THERAPEUTICS INC BIG TRADING SWING | SMMT STOCK Simply Click The Next Internet Page (JHLdCFn8fQ) - Mshale
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy - Meyka
What's Going On With Summit Therapeutics Stock Wednesday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
$Summit Therapeutics (SMMT.US)$ - Moomoo
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Bu - GuruFocus
Pullback Watch: Is Summit Therapeutics Inc forming higher highs and higher lowsQuarterly Portfolio Review & Low Drawdown Investment Ideas - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Tudor Investment Corp ET AL Takes $7.17 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Buy' Rating | SMMT Stock News - GuruFocus
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aug Selloffs: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Market Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
Stifel initiates Summit Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Stifel Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):